The global breast cancer diagnostics market size was valued at USD 3.92 billion in 2020 and is projected to expand at a CAGR of 6.7% during the forecast period, 2021 – 2028. The growth of the market is attributed to rising government efforts to raise cancer screening and diagnosis rates as well as the rising incidence of cancer.
Breast cancer occurs due to the disorderly expansion of the cells and tissues of the breast and appears as a lump surrounding the internal breast tissues, usually developing into a tumor. Breast cancer is a malignant tumor that almost exclusively affects women, with a few exceptions in adults. Breast cancer is now the most prevalent cancer in women all around the world. The number of women diagnosed with breast cancer is on the rise. Therefore, it becomes necessary for the early detection of the breast cancer among women. Early detection of cancer increases the chances of preventing the progress of the cancer and increase the chance of survival of patients significantly. Breast cancer can be detected early due to raising awareness as well as encouraging early diagnosis and screening.
Market Trends, Drivers, Restraints, and Opportunities:
- Increasing number of private diagnostic centers and development of innovative diagnostic imaging procedures are expected to boost the market expansion.
- Rising establishment of public hospitals and centers specialized for the treatment of cancer across the globe present key driving factors for the market.
- Growing demand for technologically advanced products that can improve accuracy, speed, and cost-effectiveness for cancer detection is propelling the market growth.
- Governments sponsored awareness activities and initiatives in developed countries encouraging and guiding primary care doctors to recommend cancer screening tests for patients are propelling the market expansion.
- Higher cost of diagnostics and lack of effective reimbursement rates, and budgetary restrictions among patients from developing countries are key challenges that can hamper the market growth.
Scope of the Report
The report on the global breast cancer diagnostics market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes
|
Details
|
Report Title
|
Breast Cancer Diagnostics Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
|
Base Year
|
2020
|
Historic Data
|
2018–2019
|
Forecast Period
|
2021–2028
|
Segmentation
|
Types (Imaging, Biopsy, Genomic Tests, and Blood Tests), Products (Platform-based [Next-generation Sequencing, Microarrays, PCR, and Others] and Instrument-based [Imaging and Biopsy]), Applications (Screening, Diagnostic & Predictive, Prognostic, and Research), End-users (Hospitals & Clinics, Diagnostic Centers & Medical Laboratories, and Others),
|
Regional Scope
|
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
|
Report Coverage
|
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
|
Key Players Covered in the Report
|
Hologic Inc.; Genomic Health (Exact Sciences Corporation); BD; Danaher; Koninklijke Philips N.V.; QIAGEN; Thermo Fisher Scientific Inc.; Myriad Genetics; Argon Medical Devices, Inc.; F. Hoffmann-La Roche Ltd.
|
Breast Cancer Diagnostics Market Segment Insights
Imaging segment is expected to dominate the market
Based on types, the global breast cancer diagnostics market is segmented into imaging, biopsy, genomic tests, and blood tests. The Imaging segment held a dominant market share, representing over 70.3% in 2020 and is expected to continue the trend in the coming years. The segment growth is attributed to factors such as large volume of procedures, easy accessibility, and enhanced effectiveness of imagining technology. Mammograms, ultrasound, and magnetic resonance imaging (MRI) are some of the most common imaging techniques used for screening and diagnosis. Furthermore, a number of advanced new imaging techniques for breast cancer diagnosis such as breast tomosynthesis, Molecular Breast Imaging (MBI), CT, and PET, are poised to change the landscape of breast imaging segment.
On the other hand, the blood test segment is expected to grow significantly during the forecast period due to growing research studies carried out by the research organizations and major players to ensure high efficacy of liquid biopsy tests.
Instrument-based testing segment to hold a key share market
On the basis of products, the market is bifurcated into platform-based and instrument-based. The platform-based segment is further segmented into next-generation sequencing, microarrays, PCR, and others. The instrument-based segment is also further segmented into imaging and biopsy. The instrument-based testing segment is expected to dominate the market, accounting for more than 70.2% in 2020. The segment growth is due to wide adoption of imaging devices as the first choice for general population-based screening of breast cancer patients. All patients with breast cancer undergo a biopsy to confirm their diagnosis. Many organizations, such as the National Breast Cancer Foundation, Inc., are working to raise awareness about breast cancer, the importance of early detection, and treatment options.
On the other hand, the platform-based products segment is anticipated to expand at a rapid pace during the forecast period due to innovation of the products and the higher preference of such products for targeted therapy.
Diagnostics & predictive segment to constitute a large share
Based on applications, the global breast cancer diagnostics market is segmented into screening, diagnostic & predictive, prognostic, and research. The diagnostics & predictive segment is anticipated to constitute a dominant market share representing with an impressive CAGR during the forecast period due to the increasing prevalence of genetic testing. Meanwhile, the prognostic segment is anticipated to expand at a significant growth rate during the forecast period as these tests are used to match patients with therapies, they are becoming more important.
Hospitals & clinics segment to register a robust CAGR
On the basis of end-users, the market is segmented into hospitals & clinics, diagnostic centers & medical laboratories, and others. The hospitals & clinics segment is expected to register a robust CAGR during the forecast period owing to increasing hospitalization of patients and the growing load of the disease. Patients usually prefer to undergo biopsy for confirmatory testing in hospitals after the screening test. Additionally, PET, CT, and MRI are used to track disease progression and determine the efficacy of cancer treatments.
Diagnostic centers & medical laboratories segment, however, is anticipated to grow significantly during the forecast period due to a rise in the number of government initiatives to provide different services, such as diagnostic test reimbursement.
North America is likely to dominate the market
In terms of regions, the global breast cancer diagnostics market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is likely to dominate the market due to factors such as the presence of major players, well-established diagnostic and screening infrastructure, technological advances, high patient knowledge, and favorable reimbursement policies. Meanwhile, the market in Asia Pacific segment is expected to grow at a rapid pace during the forecast period. The regional market growth is due to the incidence of breast cancer and the adoption of advanced diagnostic techniques among the patients in the region. Furthermore, growing easy policy of reimbursement guidelines and expanding healthcare infrastructure from governments present key factors pushing the market expansion.
Segments
Segments Covered in the Report
The global breast cancer diagnostics market has been segmented on the basis of
Types
- Imaging
- Biopsy
- Genomic Tests
- Blood Tests
- Others
Products
- Platform-based Products
- Next-generation Sequencing
- Microarrays
- PCR
- Others
- Instrument-based Products
Applications
- Screening
- Diagnostic & Predictive
- Prognostic
- Research
End-users
- Hospitals & Clinics
- Diagnostic Centers & Medical Laboratories
- Others
Regions
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Hologic Inc.
- Genomic Health (Exact Sciences Corporation)
- BD
- Danaher
- Koninklijke Philips N.V.
- QIAGEN
- Thermo Fisher Scientific Inc.
- Myriad Genetics
- Argon Medical Devices, Inc.
- F. Hoffmann-La Roche Ltd.
Competitive Landscape
Some of the major companies competing in the market are Hologic Inc.; Genomic Health (Exact Sciences Corporation); BD; Danaher; Koninklijke Philips N.V.; QIAGEN; Thermo Fisher Scientific Inc.; Myriad Genetics; Argon Medical Devices, Inc.; F. Hoffmann-La Roche Ltd.
Several market strategies such as mergers, acquisitions, and alliances are being used by major corporations to increase their global market share. Hologic Inc. acquired Biotheranostics and SOMATEX Medical Technologies GmbH in January 2021. Thermo Fisher Scientific, Inc. negotiated a partnership with AstraZeneca and the University of Nebraska Medical Center in September 2020 to develop innovative clinical biomarkers. In addition, the firm signed an agreement with Pfizer, Inc. in October 2018 to use BRACAnalysis CDx as a companion diagnostic with Pfizer's patented talazoparib.
